Ono Pharmaceutical Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Ono Pharmaceutical Co Ltd with three other
companies in this sector in Japan:
Santen Pharmaceutical Company Limited
sales of 195.29 billion Japanese Yen [US$1.89 billion]
of which 99%
was Pharmaceutical Products),
Nichi-Iko Pharmaceutical Company Limited
(143.51 billion Japanese Yen [US$1.39 billion]
of which 100%
was Ethical Pharmaceutical), and
Kobayashi Pharmaceutical Co Ltd
(137.21 billion Japanese Yen [US$1.33 billion]
of which 78%
was Domestic Manufacture And Sale Of Househo).
Ono Pharmaceutical Co Ltd reported sales of ¥160.28 billion (US$1.55 billion)
March of 2016.
increase of 18.1%
versus 2015, when the company's sales were ¥135.78 billion.
Sales of Tissue Cell Function Agents saw an increase
that was more than double the company's growth rate: sales were up
733.7% in 2016, from
¥2.29 billion to ¥19.12 billion.
Ono Pharmaceutical Co Ltd also saw significant increases in sales in
Loyalty Other (up 44.1% to ¥15.66 billion)
Not all segments of Ono Pharmaceutical Co Ltd experienced an increase in sales in 2016:
sales of Chemistry Therapy fell 17.8% to ¥662.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Ono Pharmaceutical Co Ltd also experienced decreases in sales in
Cardiopulmonary Medicine (down 6.9% to ¥46.65 billion)
Digestive System Medicine (down 1.0% to ¥14.59 billion)
Urology Medicine (down 1.6% to ¥4.64 billion)